CagriSema is Novo Nordisk’s fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a well-characterized GLP-1 receptor agonist. Rather than targeting a single incretin pathway, CagriSema is designed to engage two complementary signaling systems at once. This article summarizes what the molecule is, how the two components are thought to work together, what the published phase 2 and phase 3 data show, and the handling considerations relevant to laboratory research. It is written strictly for research and educational purposes.
What Is CagriSema?
CagriSema is an investigational, once-weekly, subcutaneous fixed-dose combination developed by Novo Nordisk. It combines two molecules that are each studied individually elsewhere in the peptide research literature:
- Cagrilintide — a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells. It is also studied as a standalone compound; see the Cagrilintide 5mg reference guide for its individual profile.
- Semaglutide — a GLP-1 receptor agonist already extensively documented in the literature (see our semaglutide overview and the Semaglutide 5mg guide).
The rationale behind combining them is that amylin and GLP-1 signaling act through distinct receptor systems but converge on overlapping neural circuits that regulate food intake, satiety, and glucose homeostasis. In principle, engaging both pathways simultaneously could produce additive or synergistic effects compared with either single agent — a hypothesis that the clinical trial program was specifically designed to test.
Mechanism of Action
Cagrilintide and the Amylin/Calcitonin Pathway
Amylin is normally co-released with insulin after meals and contributes to satiety, slows gastric emptying, and suppresses glucagon secretion. Native amylin has a very short half-life, which limits its usefulness as a standalone research or therapeutic tool. Cagrilintide was engineered with a fatty-acid side chain — conceptually similar to the modification used in semaglutide — that promotes albumin binding and extends its duration of action to support once-weekly use.
Pharmacologically, cagrilintide is described in the literature as a non-selective agonist of the calcitonin receptor (CTR) and amylin receptors (AMY1R, AMY3R), receptor complexes formed by CTR pairing with receptor activity-modifying proteins (RAMPs). Preclinical work indicates these effects are mediated substantially through hindbrain regions such as the area postrema, a circumventricular structure with direct access to circulating signals.
Semaglutide and the GLP-1 Pathway
Semaglutide’s mechanism is comparatively well established: it activates GLP-1 receptors expressed in the pancreas, hypothalamus, and brainstem, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, slowing gastric emptying, and reducing appetite via central pathways.
Why Combine Them
Because amylin and GLP-1 signaling engage different receptors but overlapping downstream circuits, the two agents are hypothesized to reduce food intake through partially non-redundant mechanisms. This is the pharmacological premise explored across the CagriSema clinical program, rather than a simple additive dosing of two identical mechanisms.
Research Background and Key Findings
Phase 2 — Type 2 Diabetes (Frias et al., Lancet 2023)
The first major published dataset came from a phase 2, multicentre, randomized, double-blind, active-controlled trial in adults with type 2 diabetes, led by Frias and colleagues and published in The Lancet in 2023. Co-administration of once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg produced greater reductions in HbA1c and greater body weight loss over roughly 32 weeks than either component studied alone, with the combination reported to reach close to a 2-percentage-point HbA1c reduction and around 15–17% weight loss in that study population. This trial established the initial proof-of-concept for the dual-pathway approach ahead of the larger phase 3 program.
Phase 3 — REDEFINE 1 (Obesity/Overweight, No Diabetes)
REDEFINE 1 was a 68-week, randomized, double-blind, placebo- and active-controlled phase 3 trial enrolling over 3,000 adults with obesity or overweight and at least one weight-related complication, without type 2 diabetes. Results, later published in the New England Journal of Medicine (2025), reported a mean weight reduction of approximately 22.7% with CagriSema at 68 weeks, compared with roughly 11.8% for cagrilintide alone and 16.1% for semaglutide alone in the same trial — supporting the combination’s rationale, even though the top-line figure fell short of some earlier expectations that had circulated ahead of full data readout.
Same trial, no type 2 diabetes. The combination outperformed either monotherapy.
Phase 3 — REDEFINE 2 (Type 2 Diabetes and Obesity/Overweight)
REDEFINE 2 evaluated CagriSema against placebo over 68 weeks in adults with type 2 diabetes who also had obesity or overweight. Reported mean weight reduction was approximately 15.7% among adherent participants, compared with about 3.1% for placebo — a smaller relative effect than in REDEFINE 1, consistent with the generally attenuated weight-loss response typically observed with incretin-based therapies in people with type 2 diabetes.
Regulatory Status
Based on the REDEFINE 1 and REDEFINE 2 datasets, Novo Nordisk submitted CagriSema to the US FDA in December 2025 for a weight-management indication. As of this writing, CagriSema remains an investigational, unapproved combination in most jurisdictions, and its regulatory status should be independently verified before drawing conclusions about its availability.
Consolidated Observations
Across the published phase 2 and phase 3 literature, recurring findings include:
- Greater weight loss with the combination than with either monotherapy in the same trials
- Meaningful glycemic improvements in populations with type 2 diabetes
- A gastrointestinal tolerability profile broadly consistent with other incretin-based agents
- Effects that, as with related GLP-1/amylin compounds, appear to depend on continued dosing
CagriSema vs Mono-Agent Comparators
| Compound | Pathway(s) | Trial Program | Reported Weight Loss (68 wk, no T2D) |
|---|---|---|---|
| Semaglutide | GLP-1 | STEP | ~15–17% |
| Cagrilintide | Amylin/calcitonin | Phase 1/2 | Studied mainly in combination |
| CagriSema | Amylin/calcitonin + GLP-1 | REDEFINE | ~22.7% (REDEFINE 1) |
For a broader view of where CagriSema fits among other next-generation incretin-based candidates, see our pipeline overview of next-gen weight loss peptides.
Forms, Reconstitution & Handling
Research-grade CagriSema, where available for laboratory investigation, is typically supplied as separate lyophilized components or as a co-formulated lyophilized powder, requiring reconstitution with an appropriate diluent (commonly bacteriostatic water) before use in a research setting. General handling points relevant to lyophilized incretin/amylin peptides include:
- Adding diluent slowly down the interior vial wall rather than directly onto the powder
- Swirling gently rather than shaking, to avoid mechanical stress on the peptide
- Calculating concentration precisely from the labeled peptide mass and diluent volume added
- Using the vial promptly after reconstitution and discarding solutions showing cloudiness or particulates
For mass-specific reference material, see the CagriSema 5mg guide and the CagriSema 10mg guide. Researchers working with the amylin component individually may also want the Cagrilintide 5mg guide.
Research Considerations
Published CagriSema trials used gradual dose escalation schedules over several weeks, a pattern consistent with other incretin-based and amylin-based agents and intended, in the clinical literature, to allow physiological adaptation and to reduce transient gastrointestinal effects. This is a general observation about how the compound has been studied — it is not dosing guidance, and nothing here should be read as an instruction for human administration. Any research protocol should be designed in consultation with institutional guidelines and appropriate oversight.
Researchers reviewing the CagriSema literature should also weigh:
- The combination’s tolerability profile in published trials, which mirrors gastrointestinal effects (nausea, decreased appetite, occasional vomiting) reported with GLP-1 and amylin monotherapies
- That reported weight-loss figures vary meaningfully between trial populations (with vs without type 2 diabetes)
- That cagrilintide’s amylin/calcitonin pharmacology is less extensively characterized in the public literature than semaglutide’s GLP-1 pharmacology, since it is a newer molecule
Storage & Stability
General storage principles reported for comparable lyophilized incretin and amylin peptides include:
- Lyophilized powder: store frozen or refrigerated as specified by the supplier, protected from light
- Reconstituted solution: refrigerate at 2–8°C
- In-use stability: commonly on the order of several weeks once reconstituted and refrigerated, though this varies by formulation and should be confirmed against supplier documentation rather than assumed
- Avoid repeated freeze-thaw cycles, which can degrade peptide integrity
Safety, Legality & Research Disclaimers
CagriSema is an investigational combination that, as of this writing, has not received full marketing approval in most regions; its regulatory status is evolving and should be checked independently before relying on any statement about its availability. Research-grade material of either component is not equivalent to an approved pharmaceutical product. It is manufactured for laboratory investigation only, is not produced to pharmaceutical standards for human use, and is not intended for human or veterinary consumption.
Nothing in this article constitutes medical advice, and none of it should be interpreted as instruction for self-administration. Legal status for research chemicals varies by jurisdiction and by compound; verify the rules applicable to your location and institution before acquiring or handling any research material. Anyone handling these substances should follow applicable institutional biosafety and regulatory guidelines.
Frequently Asked Questions
Is CagriSema the same as taking cagrilintide and semaglutide separately?
Not exactly. CagriSema is studied as a co-formulated, fixed-dose combination in its own trial program (REDEFINE), which is distinct from studying each compound as a separate monotherapy, even though the two components are individually characterized elsewhere in the literature.
What does the REDEFINE program consist of?
REDEFINE is Novo Nordisk’s phase 3 program for CagriSema, including REDEFINE 1 (obesity/overweight without type 2 diabetes) and REDEFINE 2 (type 2 diabetes with obesity/overweight), both 68-week randomized controlled trials.
How does CagriSema differ mechanistically from semaglutide alone?
Semaglutide acts only on the GLP-1 receptor. CagriSema adds cagrilintide, which engages amylin and calcitonin receptors through a distinct pathway, with the two mechanisms converging on overlapping appetite and glucose-regulatory circuits.
Has CagriSema been approved for use?
No. As of this writing, CagriSema is investigational; Novo Nordisk submitted it to the FDA in December 2025 for a weight-management indication, but approval status can change and should be verified independently.
Why did REDEFINE 1 results differ from earlier expectations?
Some earlier commentary anticipated weight-loss figures above 25%; the reported REDEFINE 1 result of approximately 22.7% was still statistically superior to either monotherapy in the same trial, but fell short of those informal expectations, illustrating why peer-reviewed trial data should be weighed over pre-publication speculation.
Is cagrilintide’s mechanism as well-established as semaglutide’s?
Not yet to the same extent. Semaglutide’s GLP-1 pharmacology has been studied for well over a decade across large trial programs, while cagrilintide is a newer molecule with a smaller, though growing, body of published mechanistic and clinical data.
References
- Frias JP, et al. “Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.” The Lancet. 2023.
- Garvey WT, et al. “Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity” (REDEFINE 1). New England Journal of Medicine. 2025.
- “Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes” (REDEFINE 2). New England Journal of Medicine. 2025.
- Enebo LB, et al. “Development of Cagrilintide, a Long-Acting Amylin Analogue.” Journal of Medicinal Chemistry. 2021.
- “Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.” eBioMedicine. 2025.
Last updated: July 4, 2026
Disclaimer: This information is for educational and research purposes only. Peptides are research chemicals not intended for human consumption.